GSK, all China's pharmaceutical espionage in the US
Three scientists in the US have pleaded guilty to stealing GSK trade secrets for the benefit of Chinese drugmaker Renopharma.
Article by Giuseppe Gagliano – Start Magazin 5 January 2022
All of China's pharmaceutical espionage in the United States. Here are the details.
The decisive role that the FBI - which, as we know, depends from a juridical point of view on the American Department of Justice - has played and plays in the contrast of foreign espionage
present in the United States to the detriment of American civilian and military companies.
From this point of view, Chinese espionage has reached very high levels of sophistication and above all capillarity, as demonstrated by the story we will discuss.
A third former GlaxoSmithKline (GSK) scientist has pleaded guilty to stealing trade secrets benefiting Chinese pharmaceutical firm Renopharma, backed by funding from the Chinese regime, according to reports declared by the US Department of Justice.
Lucy Xi, 44, a former resident of Malvern, Pennsylvania, is the third person to plead guilty to espionage involving three co-defendants, Yu Xue, Tao Li and Yan Mei, to whom Lucy Xi was married.
According to the Justice Department, Xi and his co-defendants set up Renopharma in Nanjing, China, to research and develop cancer drugs.
However, the three were also employed at British drugmaker GSK's plant in Upper Merion, Pennsylvania, where they developed biopharmaceuticals.
Prosecutors said they used their positions at the company to steal trade secrets from their employer for the benefit of Renopharma, which has received financial backing and subsidies from the Chinese regime.
According to the Justice Department, Xi sent her husband a GSK document in 2015 containing confidential data and information and trade secrets, including a summary of GSK's research on monoclonal antibodies, lab-made proteins that mimic the immune system's ability to fight back. infections, such as viruses.
Related news: USA. GSK scientists accused of stealing cancer drug research secrets
GSK rehires whistleblower suspected of corruption allegations in China
Novartis steers clear of Chinese generics from its Gilenya for multiple sclerosis
